Metabolomics studies by NMR by Nepi, Stefano
University of Florence 
 
International Doctorate in Structural Biology 
Cycle XXII (2007-2009) 
 
 
 
 
Metabolomics studies by NMR 
 
Ph.D. thesis of 
Stefano Nepi 
 
 
 
Tutor      Coordinator 
 
Prof. Claudio Luchinat  Prof. Claudio Luchinat 
 
S.S.D. CHIM/03 
This thesis has been approved by the University of Florence, 
the University of Frankfurt and the Utrecht University 
                                                                                              1 
 
1 INTRODUCTION..................................................................................................................... 4 
Metabolomics in the system biology........................................................................................ 5 
Analytical technologies in metabolomics ................................................................................. 7 
Metabolomics and disease ....................................................................................................... 9 
Future Applications................................................................................................................. 10 
Chemometrics methods.......................................................................................................... 11 
Bibliography ............................................................................................................................ 16 
2 METABOLOMICS STUDIES BY NMR..................................................................................... 22 
Aim of the work ...................................................................................................................... 23 
3 CELIAC DISEASE AND METABOLOMICS............................................................................... 26 
Celiac Disease.......................................................................................................................... 27 
Definition and Etiology........................................................................................................ 27 
Prevalence and Incidence ................................................................................................... 27 
Clinical Manifestation of Celiac Disease ............................................................................. 28 
Diagnosis and Therapeutics ................................................................................................ 28 
Metabolomic study of Celiac Disease ..................................................................................... 29 
Aim of the work .................................................................................................................. 29 
Results and Discussion ........................................................................................................ 30 
Conclusions and Perspectives ............................................................................................. 36 
Bibliography ............................................................................................................................ 38 
4 BREAST CANCER AND METABOLOMICS.............................................................................. 42 
Breast Cancer .......................................................................................................................... 43 
Introduction and classification............................................................................................ 43 
Etiology and epidemiology.................................................................................................. 44 
Clinical manifestations and signs of breast cancer ............................................................. 45 
Diagnosis and Therapeutics ................................................................................................ 45 
Metabolomic study of Breast Cancer ..................................................................................... 47 
                                                                                              2 
 
Aim of the work .................................................................................................................. 47 
Results and Discussion ........................................................................................................ 48 
Conclusions and Perspectives ............................................................................................. 52 
Bibliography ............................................................................................................................ 53 
5 METABOLIC PHENOTYPES (METABOTYPES) IN HUMAN URINE.......................................... 55 
Background ............................................................................................................................. 56 
Aim of the work ...................................................................................................................... 57 
Results and Discussion............................................................................................................ 58 
Bibliography ............................................................................................................................ 65 
6 METABOLOMICS STUDIES ON HUMAN PLASMA ................................................................ 67 
Aim of the work ...................................................................................................................... 68 
Altered Blood Parameters................................................................................................... 68 
Peculiar Behaviours............................................................................................................. 69 
SNPs .................................................................................................................................... 69 
Partial Results and Perspectives ............................................................................................. 71 
Bibliography ............................................................................................................................ 76 
7 CONCLUSIONS AND PERSPECTIVES..................................................................................... 78 
8 MATERIALS AND METHODS ................................................................................................ 81 
Sample Preparation ................................................................................................................ 82 
NMR Experiments and Bucketing ........................................................................................... 82 
Multivariate Statistical Analysis .............................................................................................. 83 
Principal Component Analysis (PCA)....................................................................................... 84 
Partial Least Square (PLS) regression and derived methods .................................................. 88 
Bibliography ............................................................................................................................ 89 
9 PUBLICATIONS..................................................................................................................... 90 
List of publications .................................................................................................................. 91 
Author’s contribution to each work........................................................................................ 91 
 3 
 
 
 
 
 
 
A Cristina 
Ai miei genitori 
 
 
 
 
 
 
 
 
 
 
 
 
At last gleams of light have come,  
and I am almost convinced (quite contrary to opinion I started with) 
 that species are not (it is like confessing a murder) immutable. 
Charles A. Darwin 
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Metabolomics in the system biology 
The decoding of human and other mammalian genomes during the 1990s caused a 
strong evolution in the field of molecular biology, giving birth to new fields of science, 
called “omics” sciences. All these new “omics” sciences provided a great number of 
biological features about complex systems, giving the scientific community a new point 
of view on this life form. Mammalian animals and men can presently be considered as 
“superorganisms” (1), in which environmental and lifestyle effects completely 
influence biomolecular organization. Such factors can also modify gene and protein 
expression and metabolites levels, leading to differences between various individuals 
(inter-individual), but also inside the same subject (intra-individual). Moreover, also 
the symbiotic gut microflora interacts with the host with a specific metabolism and a 
genome that usually is not well-known. This great complexity leads to the definition of 
“Global System Biology” (2) to highlight the necessity to integrate multivariate 
biological information to better understand the behaviour of the so called 
superorganism. The first born of these new sciences is transcriptomics, which studies 
the determination of gene expression changes between subjects (3), and proteomics, 
which deals with  the determination of all protein expression changes in a cell or tissue 
(4). In this context both metabolomics and metabonomics are defined (see Figure 
1.1). The term metabonomics is defined as “the quantitative measurement of the 
dynamic multiparametric metabolic response of living systems to pathophysiological 
stimuli or genetic modification” (5), while the term metabolomics is introduced later as 
the “comprehensive and quantitative analysis of all metabolites” in a system (6). Even 
if there is a difference between the two terms, they are almost considered as 
equivalent  and used interchangeably by the scientific community (1) as well as in this 
text. Though the term metabonomics was coined many years later, the concept of 
metabonomics was  born with the first simultaneous analysis of metabolites present in 
biological fluids through 
1
H NMR spectroscopy in the 1980s (7). The data obtained 
from this kind of analysis are very complex and they were interpreted by using a 
multivariate statistics approach to classify the samples according to their biological 
status (8-9).                          
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Figure 1.1 The “omics” sciences. 
Most metabolomics studies involved common biofluids as urine and serum/plasma 
that are easily obtainable from mammalians, especially from humans. Moreover, these 
two types of biofluids are obtained in a non- or poorly-invasively way and they are 
easy to find and collect because they are commonly used for many other biological 
analyses. Hence they can be used for disease diagnosis and in a clinical trials setting for 
monitoring drug therapy. Besides, all biological fluids are useful for metabolomics 
analysis, e.g. cerebrospinal fluid, synovial fluid, exhaled breath condensate, saliva and 
so on (10).  There are some problems associated to the use of these peculiar fluids for 
which they are not normally analyzed: poor collectable quantity, highly-invasive 
extraction techniques, poor metabolites information carried on. In addition, some 
metabolomics studies have used tissue samples and their aqueous or lipid extraction 
(11) or in vitro cell systems (12).  The number of different metabolites in these human 
fluids is unknown; estimates range from a minimum of 2,000 to 3,000 to a maximum of 
around 20,000 metabolites, compared with an estimated 23,000 genes and 60,000 
proteins (13). Small metabolites, that are low-molecular weight compounds that serve 
as substrates and products in various metabolic pathways, are of particular interest to 
metabolomics researchers. These small molecules include compounds such as lipids, 
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sugars, and amino acids, as well as bioactive products acting at very low 
concentrations in tissue signalling functions (14). 
Analytical technologies in metabolomics 
The main analytical techniques employed in metabolomics are nuclear magnetic 
resonance (NMR) spectroscopy and mass spectrometry (MS). NMR spectroscopy is a 
non-destructive technique that provides detailed information on molecular structure 
of both pure compounds and complex mixtures (15), and for these reasons can be 
applied to metabolomics studies. High-throughput NMR spectroscopy consists of an 
automatic sample preparation step and a fast 
1
H NMR analysis, about eight minutes 
for each sample. The automatic sample preparation involves addition of buffer and 
D2O, as magnetic field lock signal for spectrometer; it enables to prepare a significant 
number of samples in a short time. The obtained spectra profiles are essentially the 
superposition of 
1
H NMR spectra of thousands different small molecules (up to 2500 
for urine, up to 200 for serum/plasma) present in sample at concentration >1 µM (16). 
A typical 
1
H NMR spectrum is obtained using water suppression techniques and adding 
TSP (sodium trimethylsilyl [2,2,3,3-
2
H4]propionate) as internal reference, it contains for 
urine predominantly sharp lines due to small molecules, while for serum and plasma 
both broad and sharp signals are present due respectively to macromolecules, as 
lipoproteins, and low molecular metabolites. These broad signals of macromolecules 
can be suppressed by applying  a Carr-Purcell-Meiboom-Gill (CPMG) filter to a standard 
1D sequence. One of the principal disadvantages of the NMR approach is the difficult 
identification of all metabolites in the samples, a process that involves a large number 
of techniques like two-dimensional NMR experiments. Indeed the 
1
H NMR of biological 
fluids is very complex and even though many resonances can be directly assigned  
basing on chemical shifts, multiplicity and by addition test, various two-dimensional 
NMR experiments are necessary to increase, but not to complete, the identification of 
biomarkers in biofluids. These 2D experiments include: i) 
1
H-
1
H J-resolved (J-res), to 
attenuate macromolecules signals and to give more information about multiplicity and 
coupling patterns ii) 
1
H-
1
H correlation spectroscopy (COSY) and 
1
H-
1
H total correlation 
spectroscopy (TOCSY), to provide 
1
H-
1
H spin-spin coupling connectivities iii) various 
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heteronuclear experiments that use information coming from other types of nuclei as 
13
C, 
15
N and, if it is present, 
31
P, as for example 
13
C-
1
H HSQC, to obtain information on 
the direct coupling 
13
C-
1
H.  
Mass spectrometry is a destructive technique that requires a very poor quantity of 
samples. Over the last few years its application to mammalian study has been 
increasing, especially for its great sensitivity, higher than NMR, and because it is a 
major technique for molecular identification, through the use of tandem methods for 
fragmention studies or of Fourier transform MS for a very accurate mass 
determination (1). Mass is usually coupled with chromatographic techniques as GC 
(Gas Chromatography) and LC (Liquid Chromatography) to separate different classes of 
substances (17).  The process of ionization, for biofluids as urine, is usually generated 
by the electron spray (ESI) method, and then both positive and negative 
chromatogram are measured. A three-dimensional chromatogram (retention time, 
mass, intensity) is generated by applying the HPLC (or GC)-MS approach. The great 
advantage is the possibility to cut off any mass peak from interfering substance (as for 
example drug metabolites or contaminant) without altering the dataset (1). 
It is possible to affirm that the two techniques are complementary for fully 
characterization: even if MS is better for identification of metabolites and for 
sensitivity, NMR is particularly useful for distinguishing isomers, informing on 
molecular conformation and studying molecular dynamics (1). Moreover, both NMR 
and MS techniques are being improved and developed.  
The sensitivity problems of NMR are partially solved by using cryogenic probes, where 
the detector coil and the pre-amplifier are cooled around 20 K, increasing the signal-
noise ratio (18); moreover, the recent development of a technique called high 
resolution 
1
H magic angle spinning (MAS) made feasible the acquisition of data on little 
pieces of tissue without any treatment; indeed, with the rapid spinning of the sample 
at an angle of 54.7° relative to magnetic field applied, it is reduced the line broadening 
effect and the associated loss of information (19-21). As far as MS metabolomics is 
concerned, the introduction of UPLC (Ultra Performance Liquid Chromatography) 
enabled better peak resolution and further increase in sensitivity and speed analysis 
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and it is still successfully applied to metabolomics studies (as UPLC-MS) (22). Finally, 
some “hyphenated” approaches  like HPLC-NMR-MS (23), in which each eluting HPLC 
peak is split to enable a parallel analysis by NMR and MS, are still  used for a complete 
metabolic identification. 
 
Metabolomics and disease 
However, the strongest point of NMR metabolomics is associated to the capability to 
analyze, at the same time,  all the metabolites present in biofluids with this approach. 
It is possible to obtain information about the status of a sample (and therefore of a 
subject) through the analysis of the so- called fingerprint. In NMR metabolomics the 
term fingerprint usually indicates the complete NMR profile of each analyzed sample. 
Applying statistical techniques, various samples are comparable through the exam of 
their fingerprint, without requiring the knowledge of all metabolites. This constitutes a 
true revolution to identify metabolic differences among various samples. Indeed 
metabolomics is still used for many purposes as for example to relate toxic or 
therapeutic effects of xenobiotics to normality (24), but one of the principal 
application of metabolomics is to aid human disease diagnosis. Several inborn errors of 
metabolism in children, for instance,  are diagnosed with the use of NMR spectroscopy 
of urine and serum (25). Moreover, in the last few years the use of metabolomics 
approach has increased to provide significant information on a wide range of 
pathologies, as cancer (26), ischemia-riperfusion (27), meningitis (28), diabetes (29), 
neurological disorders (30), liver fibrosis and cirrhosis (31), inflammatory bowel 
disease (32) and so on. Exploring pathologies through the holistic metabolomics 
approach can be very important to get new lights inside their mechanism and their 
impact on humans and animals. Nevertheless, it is possible to obtain a fast and non 
invasive diagnosis (pre-diagnosis) of some of them, as it is observable by reading a 
work about coronary artery disease (33), in which the sensitivity and the specificity of 
the test is either 92% or 93%, and therefore this allows to distinguish between normal 
coronary artery subjects and triple coronary vessel disease subjects with an high value 
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of accuracy. Sensitivity, specificity and accuracy are biostatistical parameters well 
explained in Table 1.1.  
While for angiogenesis the complete fingerprint of the illness is the responsible of the 
discrimination between healthy and sick subjects, it is also possible to highlight specific 
biomarkers for a selected pathology, or specific altered pathways, with metabolomics. 
This can be achieved without a priori knowledge about molecular characteristics. 
Therefore, metabolomics can be also used as a screening for markers and, once these 
are identified, can lead to the successive development of specific kits for a cheaper and 
extensive diagnosis of diseases. 
  Condition (as determined by GOLD STANDARD)  
  Positive Negative  
Positive True Positive (TP) False Positive (FP) (Type I error) Positive Predicted Value  
Test Outcome Negative False Negative (FN) (Type II error) True Negative (TN) Negative Predicted Value 
  Sensitivity (TP/FN+TP) Specificity (TN/FP+TN) Accuracy (TP+TN/TP+TN+FP+FN) 
Table 1.1  Biostatistical parameters. 
Future Applications 
One of the long-term goals of metabolomics is clearly the understanding of the existing 
relationships between genetic polymorphisms of different individuals and their 
metabolic fingerprint, in order to completely understand the response of different 
organisms to external stimuli. The achievement of this aim could be very important in 
the field of pharmacometabolomics, leading to personalized healthcare (34). Thus, an 
individual’s drug treatment will be tailored so as to achieve maximal efficacy and avoid 
adverse drug reactions. In order to solve this purpose it is necessary to exactly 
determine the genetic and environmental influences on the basal metabolic fingerprint 
of an individual, since these will also influence the outcome of a chemical intervention. 
In this direction a great improvement is obtained with the demonstration of the 
existence of unique individual metabolic phenotypes, called metabotypes (35-36). 
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Moreover, there is a wide range of current and emerging applications of 
metabolomics: i) investigation of invertebrates tissue extracts and biofluids as 
monitors of environmental toxicity (37-38) ii) investigation of plant biofluids (39) iii) 
studying of relationship between specific changes in gene expression and alteration of 
biochemical process (functional genomics) (40) iv) epidemiological study on large 
cohorts of biofluids samples to highlight differences in metabolism of various 
populations across the globe (41). 
Chemometrics methods 
Once the spectra of each biofluid are collected, it is necessary to analyze these data. 
Both NMR and mass spectrum can be thought of as a multidimensional set of 
metabolic coordinates, whose values are the spectral intensity at each data point (ppm 
for NMR and retention time for mass). Starting from these data, the principal aims of 
metabolomics can be summarized in four goals: i) visualization of overall differences, 
trends and relationships between samples and variables, ii) determination of whether 
there is a significant difference between groups, for instance between healthy subjects 
and sick subjects for a pathology, iii) highlighting all metabolites that are responsible 
for these differences and, maybe a little less important, iv) construct a predictive 
model for new samples. Multivariate statistical analyses are the key to achieve these 
goals. At present with the NMR spectra the variables are obtained by “bucketing”. 
Bucketing is a procedure used to reduce the total number of variables. One bucket (or 
bin) is a little slice of spectrum. The corresponding intensity of this slice is calculated in 
order to obtain our primary variables for each bucket. Obviously, the size of the 
buckets is one of the parameter to choose, even if 0.02 ppm is the commonest size. 
One of the simplest multivariate techniques largely used in metabolomics is PCA 
(Principal Component Analysis). PCA is a linear technique that expresses the maximum 
of variance in a data set through a small number of factors called Principal 
Components (PCs). Each PC is obtained as a linear combination of the primary 
variables (buckets). The first PC (PC1) expresses the maximum percentage of 
variability, then the value of variance quickly decreases in a way that the first PCs are 
the responsible for the great part of variability, while the last PCs are significantly less 
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important and express noise variability. Moreover, each PC is orthogonal and therefore 
independent with respect to the others. The conversion of data matrix into PCs gives 
two new matrices: score matrix and loading matrix. The scores express the coordinates 
for the samples in the model, indeed every dot in a score plot represents a single 
spectrum, and may be considered the new variable. The loadings represent the way in 
which the buckets are linearly combined. Hence, in the loading plot, each point 
represents a different spectral intensity and how the old variables weight to 
discriminate between samples, practically which buckets are responsible for the 
maximum variance. 
Moreover, in metabolomics, it is possible to apply also supervised methods of analysis. 
The most used of these methods is PLS (Partial Least Square) (42). PLS relates a matrix 
containing data that are independent from the samples, such as spectral intensity, 
called X matrix, with a matrix containing dependent variables (Y matrix), such as 
information about the nature of the samples (healthy or sick in case of studies of 
pathologies). In order to obtain valid data from PLS and, generally, from all supervised 
methods, it is necessary to split the samples into two sets, called “training set” and 
“validation set”. The training set is used to build the mathematical model which is used 
to analyze the validation set. Naturally many random and variable training sets and 
validation sets can be built to correctly and fully investigate the data through a robust 
model. One recent modification of the PLS method is constituted by the OPLS 
(Orthogonal Projection to Latent Structures method) (43), that is used to remove 
irrelevant and confusing parameters. The basic idea of OPLS is to separate the 
systematic variation in X matrix in two parts, one linearly related to Y matrix, and the 
other unrelated (orthogonal) to Y. This partition facilitates model interpretation and 
model execution on a new set of samples. Both OPLS and PLS can be used combined 
with DA (Discriminant Analysis) to establish the optimum of discrimination between 
samples. 
Only linear methods are described above. These kinds of methods are the most used in 
metabolomics, on the other hand the distribution of  metabolic data is often not well 
approximated by a multivariate normal, due to non-normality in the distribution of the 
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single metabolites or, more commonly, to the combination of several groups of 
normally distributed metabolites. Therefore the application of PCA, or corresponding 
supervised methods like PLS, can bring to the lack of information. For these reasons 
the application of various non-linear methods of multivariate analysis can be very 
useful in metabolomics. However, it is necessary to consider that non-linear methods 
employ more tunable parameters, which can lead to a difficult interpretation of data 
and to a reduction of model robustness. Moreover, they are usually more susceptible 
to overfitting and to the effect of noise. Therefore, even if their application is 
theoretically very useful, they have to be applied with extreme caution. Naturally also 
these methods are divided into unsupervised (as PCA) and  supervised (as PLS); a brief 
description of some of them is presented below. 
HCA (Hierarchical Cluster Analysis)  It is widely used in all areas of science and it is 
recently applied to a metabolomic study to explore a set of 20 toxicology studies (44). 
These methods cluster the data forming a tree diagram (also called dendrogram), in 
which the relationships between samples are expressed. The algorithm starts 
calculating the distance between all pairs of data points and, then, proceeds finding 
the closest pairs of cluster at each iteration (initially each cluster consists of a single 
data point). The main problem  in the application of these methods to metabolomic 
studies is that the reproducibility is not good,; the inclusion of new data,for instance, 
requires a complete re-computation of the dendrogram that can lead to a new 
structure not necessarily similar to that generated from the previous training set. 
Moreover, HCA does not generate diagnostic information about what features are 
responsible for the classification in sub-clusters. 
SOMs (Self-Organising Maps)  The SOMs is an unsupervised method of classification 
that reduces the dimensionality of the data through the creation of an array of nodes, 
each one  described by a “codebook” vector. During the training, each sample is 
presented to the map and the node with the closest reference vector is selected as the 
final node for the sample (also called “winning node”). Clearly the number of chosen 
nodes is a fundamental variable; with few nodes, for instance, the map does not 
represent faithfully the data distribution, while with a large number of nodes 
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phenomena as overfitting and noise susceptibility influence the analysis. Moreover, 
another disadvantage is associated to the final position of similar clusters, that may 
end up in distant parts of the SOM despite their similarity. For all these reasons they 
are not widely used in metabolomics, even if in a study on breast cancer SOMs are 
applied in combination with kNN  (k-Nearest Neighbour) classification (45). In R 
software some scripts to apply supervised SOMs have been developed. 
K-means clustering  This unsupervised algorithm is widely used in some fields as 
transcriptomics. It starts to work selecting the desired number of clusters and 
randomly assigning their center. For each iteration data points are classified through 
the assignment to one of the clusters, basing on the closest cluster center. After this 
addition the new cluster centres are recomputed. Despite their popularity, k-means 
are not often applied to metabolomics. The main reasons are the absence of diagnostic 
tools and associated visualization. In order to avoid these disadvantages this technique 
can be applied in combination with other statistical procedures, as in a metabolomic 
study of plant and marine invertebrate extracts with HCA (46). 
kNN (k-Nearest Neighbour) classification  This is the simplest of all supervised 
classification approaches. Every sample is classified to the class most frequently 
expressed among the k nearest neighbour. Therefore the k is the fundamental 
parameter to set. Small values of k can lead to the construction of a model subject to 
significant statistical fluctuations, while large values of k reduce statistical errors but 
can smooth out many details of the class distribution. As k-means, this method gives a 
classification of the sample without associated visualization and interpretation of data 
and, therefore, it is not applied only  in metabolomics (46,47). 
ANNs (Artificial Neural Networks)  ANNs is one of the most popular supervised method 
for pattern recognition in biomedical area. It consists of a network of nodes. Each of 
these nodes performs an operation to give a single output. Theoretically the nodes can 
be divided into three layers: i) input nodes ii) hidden nodes and iii) output nodes. 
Generally in metabolomic studies each input node  is formed by each single spectrum, 
while each output node represents each class of samples (even if it is better to have 
one more output node corresponding to an unknown class). Each hidden node 
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receives some information from various input nodes  and re-combines this  
information using a non-linear activation function to give a signal to the output nodes. 
For their great versatility the ANNs are still applied to some metabolomic studies (48-
51), even if this technique is not so easy to use. Indeed, some experience is required to 
select the optimal architecture (for instance the number of hidden nodes) in order to 
avoid error in spectra classification. Moreover, it is often difficult to clearly understand 
the connection weights to completely understand the parameters (buckets in our case) 
responsible for identification. 
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Metabolomics has established itself as an useful complement to the characterization of 
pathologies. The metabolome, that is considered the downstream of genome, transcriptome 
and proteome, is the best representation of a healthy or diseased phenotype of an organism. 
Indeed, metabolome amplifies changes caused by a biological perturbation. As opposed to 
metabolomics, which places a greater emphasis on comprehensive metabolic profiling, 
metabonomics is more often used to describe multiple (but not necessarily comprehensive) 
metabolic changes caused by a biological perturbation. Nuclear Magnetic Resonance (NMR)-
based metabonomics offers evident advantages in contrast with knowledge-guided search of 
metabolites in pathological samples. NMR-based metabonomics makes no assumptions on the 
identity of the metabolites that are relevant for the selected pathology. Information on the 
metabolite pattern alterations that can be significantly associated to the pathology is directly 
obtained through statistical analysis of the NMR profiles.  Usually, metabonomics does not rely 
on the measurement of a single metabolite-associated peak(s) but analyze spectra as whole: 
metabonomic profiles are essentially the superposition of the 
1
H NMR (in the most popular 
version of NMR-based metabonomics) spectra of tens to thousands different small molecules 
(up to 2500 in the case of urine) present in the sample at  > 1 µM concentration.5 In principle a 
NMR profile contains qualitative and quantitative information on all of them.  Small changes in 
enzymes concentrations can reflect in considerable alterations in intermediate products and 
because the fact that metabolic networks are connected by few high concentrated nodes, that 
can be investigated by NMR-based metabonomic analysis of biological fluids such as serum, 
plasma, and urine. MetNoMet (comparison between samples coming from the previous three 
breast cancer projects after starting therapy to highlight possible difference between 
metastatic and non-metastatic subject)  serum. 
Practically metabolomics seems to have a staggering diagnostic potential, explaining what 
actually happens to an organism and not what might happens as genomics or proteomics. 
Moreover its new approach, that is the contemporary analysis of all metabolites in a biofluid, 
indipendently of their assignment and their classes (fingerprint analysis) can be very useful to 
get new hints on various classes of pathologies.  
Aim of the work 
In this context my research projects have been developed during these three years. The 
general aim of the research can be splitted in two. First of all I tested the great potential of 
metabolomics in diagnosis and prognosis of pathologies or as new tools to discover biomarkers 
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and to understand complex biological mechanism of a pathology. In order to solve this goal, 
two diseases are selected: celiac disease (CD) and breast ductal carcinoma. CD is chosen 
because can be considered as a “metabolic” pathology or, at least, a pathology that seriously 
affects the metabolism of ill subjects. Indeed the mal-absorption associated to the pathology 
causes significant alteration in the metabolism of sick subjects. On the other hand, breast 
ductal carcinoma is a pathology with a great impact in the human population, especially in 
women. Therefore it is studied for many points of view and any contribution is important and 
fundamental to the definition of its onset and progression. Furthermore it is necessary to 
remember that almost all kinds of tumors can evolve in the metastatic form. The metastatic 
cells develop mechanisms in order to pass basal membrane of tissues and, then, the blood 
stream transfer them from one organ to others. Thus, the metabolomic studies of 
serum/plasma of subjects affected by a carcinoma is clearly very useful to define a general 
metastatic risk and to single out a specific fingerprint of the metastasis. Finally the application 
of metabolomics approach to these (but also to other) pathologies results to be very useful in 
order to highlight an eventual correlation between metabolic fingerprints and specific 
pathologies, try to diagnose and evaluate the advancement of a pathology and to evaluate for 
each subject the risk factors to contract a pathology, single out new biomarkers and study in 
detail several metabolic pathways. 
Nevertheless the metabolomic analysis of healthy subjects is clearly interesting and, therefore, 
constitutes the second principal aim of my research activity. Essentially the study of healthy 
subjects is important in metabolomics to have a clear definition of what is the variability. 
Indeed, metabolomics analyzes all metabolites that are present in a biofluid. Thus, when 
samples of subjects that have a specific pathology are analyzed, their metabolism and, 
consequently, their fingerprint is heavily affected by diet, physical activity and, in general, 
other environmental factors, besides than pathology. In this way the repeated study of urine 
samples (see chapter 5) coming from different subjects is very important in order to define 
better inter- and intra-variability and what are the effects on the metabolome of both 
environmental and genetic factor. Furthermore it is important to consider that the definition 
of healthy state is not completely clear and unambiguous. Therefore the metabolomics study 
of healthy individuals can be very useful to characterized their healthy states and to 
understand if it is possible to divide the healthy subjects basing on their metabolism. This can 
lead to define some classes of healthy subjects that present different “responses” to various 
stimuli such as drug intake, diet, physical activity and so on.  
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Finally each single metabolomic project developed during these three years, presents peculiar 
goals and aims that can be also significantly different from each other. These heterogeneous 
goals are separately treated in the each proper project chapter. 
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Celiac Disease 
Definition and Etiology 
Celiac disease (CD) (also called coeliac disease or sprue) is an autoimmune disorder of 
the small intestine caused by intolerance to gluten that occurs in people of all ages. It 
is characterized by immune-mediated enteropathy resulting in mal-digestion and mal-
absorption (1).  Although no pharmaceutical treatment is actually known to deal with 
it, a lifelong free-gluten diet is sufficient to reverse the symptoms and to allow the 
patient to spend a normal life (2). In particular, the pathology is caused by an immune 
reaction to gliadin, a gluten protein normally present in wheat, barley and rye. Upon 
exposure to gliadin, the enzyme tissue trans-glutaminase (tTG) modifies the protein, 
and the immune system cross-reacts with the small-bowel tissue, causing an 
inflammatory reaction, that leads to a truncating of the villi lining the small intestine 
(called villous atrophy). This interferes with the absorption of nutrients, because the 
intestinal villi are responsible for absorption (3). CD is defined as a multi-factorial 
disorder in which both genetic and environmental factors play a crucial role in 
pathogenesis (4). Genetically it is associated with specific alleles: HLA-DQ2 and HLA-
DQ8. HLA-DQ2 is expressed in more than 90% of people with CD (5). However, the 
expression of these two alleles is not sufficient to develop CD and, moreover, results 
from studies on siblings and on homozygous twins suggest that they are not the main 
causes of the disease onset (6,7). 
Prevalence and Incidence 
In epidemiology, prevalence is a statistical parameter associated to a disease that 
represents the total number of cases in a population at a given time divided by the 
number of individuals of the same population. Historically for celiac disease the 
prevalence was considered of about 0.02% (8), but the introduction of new diagnostic 
practices caused an increase in this value. At present  the prevalence is considered to 
be between 0.05% and 0.27%, even if for some populations of Southern Europe (as 
Italian), India and U.S.A. the prevalence is indicated to be between 0.33% and 1.06% in 
children (for Sahrawi people is 5,66%) and between 0.18% and 1.20% in adults (9-10).  
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 Incidence is a measure of the risk of developing some new conditions within a 
specified period of time. Some studies report a general decline of incidence during the 
1970s and a successive rising during the late 1980s and 1990s contemporary to the 
development of new methods of analysis and diagnosis (9, 11-13). In general incidence 
conveys information about the risk of contracting the disease, whereas prevalence 
indicates how widespread the disease is. 
Clinical Manifestation of Celiac Disease 
The symptoms of CD are various. Abdominal distension and pain, vomiting, 
steatorrhea, diarrhea, weight of loss and fatigue are relatively common symptoms in 
CD patients. Children between nine and twenty-four months tend to present - 
together with bowel symptoms - also  growth problems and pyloric stenosis. The 
described symptoms are relatively common for gastrointestinal mal-absorption 
pathologies. However, in case of CD, most patients have a constellation of other 
clinical manifestations, such as anemia; moreover, several other conditions are 
described associated to CD as T-cell lymphoma (14-15), osteoporosis (16), neurologic 
disease (17-18) and some autoimmune disorders (19), like type 1 diabetes (20), 
autoimmune thyroiditis (21) and Addison’s disease (22). Nevertheless, there are two 
types of CD that do not manifest themselves with significant symptoms or associated 
pathologies. These two forms of CD are called: silent CD and latent CD. While in the 
silent form the patients do not show any symptoms but present alteration of intestinal 
mucosa (villous atrophy), in the latent form the patients do not show both symptoms 
and intestinal damage but only have a clear predisposition to the pathology (positivity 
to anti-gliadin (AGA) and anti-endomysium (EMA) antibodies testing).  
Diagnosis and Therapeutics 
Several tests could be used to diagnose CD, including serological and endoscopic tests.  
The biopsy by fiber-optic endoscopy is the test which carries the higher value of 
sensitivity (about 100%) and lower frequencies of error, due to the possibility to have 
false positive (specificity is about 61%). In each case endoscopy represents a very 
invasive test; nowadays it is used to definitively confirm the presence of the CD in 
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patients with positive serology and/or high-risk symptoms, as weight loss, anemia 
(more than 120 g/l in females and 130 g/l in males) and diarrhea (23). Serological tests 
are the first approach used to determine CD. Most used tests are the indirect immune-
fluorescence measures of four antibodies : IgA-anti-reticulin (ARA) , IgA-anti-gliadin 
(AGA) and, above all, IgA-anti-endomysium (EMA) and IgA-anti-transglutaminase (tTG) 
(24). In parallel total levels of all IgA are checked to avoid the possibility to have false 
negative results associated to celiac patients with IgA deficiency; in this case IgG 
antibodies could be useful to diagnose CD (25). These tests have a very high value of 
sensitivity (over 90%) and specificity (about 99%) (26). Similar values of specificity and 
sensitivity are associated with anti-tTG test, even if it is quicker and easier than anti-
EMA test (27). Although serology appears as the better first approach to diagnose CD it 
is interesting to note that some cases of apparent seronegative CD occur, even if in 
presence of normal serum IgA (28). 
Historically the only one therapeutical approach in CD is a complete gluten-free diet 
(2). After a period of diet, varying from a few weeks to some months, all the 
symptoms, included villi atrophy, are totally reversed. All other tried strategies, for 
example the use of bacterial prolyl endopeptidase as dietary supplement to degrade 
anti-gliadin peptides (29), failed in vivo. 
Metabolomic study of Celiac Disease 
Aim of the work 
Although CD is a  widely studied pathology, many questions still remain unsolved . In 
particular, some symptoms and effects associated to the pathology are not well 
explained, for example up to 87% (30) of CD patients present chronic fatigue, that 
sometimes is the only symptom of undiagnosed CD (31-32); the origin of this syndrome 
is still unravelled and its attribution to mal-absorption is not sufficient. Clearly CD is a 
pathology with a direct impact on the metabolism, therefore the metabolomic 
approach, giving a holistic point of view of the pathologies, could be helpful to better 
understand some of these  unclear CD mechanisms. To solve these purposes of 
investigation, thirty-four both urine and serum samples of different celiac patients (7 
 30 
 
males, 27 females, mean age 38.7 +/- 13.7 years) and thirty-four both urine and serum 
samples of different healthy subjects (13 males, 21 females, mean age 37.6 +/- 14.8 
years) are collected and analyzed. Moreover, it is also interesting the metabolomic 
analysis of follow-up patients. Normally the reversibility of the CD after the start of the 
gluten-free diet is only determined by the disappearing of the common symptoms. The 
analysis of the gut mucosa is not usually done by the patient when the pathology 
becomes asymptomatic, because is very invasive and tiresome. Thus metabolomic 
analysis of the follow-up samples should be useful: i) to validate the novel approach ii) 
to suggest a non invasive method of diagnosis of the CD reversibility. For this purpose 
urine and serum samples are also collected after three (n=17, 3 males, 14 females, 
mean age 40.5 +/- 14.1 years), six (n=10, 1 male, 9 females, mean age 38.7 +/- 13.8 
years) and twelve (n=13, 2 males, 11 females, mean age 41.3 +/- 11.5 years) months of 
treatment with a strict gluten-free diet.  
Results and Discussion 
Four different statistical analyses are used to discriminate between celiac patients and 
healthy subjects (HS). The best discrimination was obtained using six-fold PLS-RCC-
SVM method on the test sets with value of accuracy of 94.1% for serum CPMG spectra, 
92.6% for serum NOESY spectra and 83.3% for urine NOESY spectra as reported in 
Table 2.1.  
 
Table 2.1 Classification results for sensitivity, 
specificity and accuracy obtained for serum CPMG 
and NOESY spectra and urine NOESY spectra. 
These high values of discrimination are obtained by a simple statistical analysis and 
they demonstrate the existence of a metabolic signature for celiac disease. In details, 
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the lowest values of discrimination for the urine are probably related to the higher 
day-per-day variability expressed in the metabolic profile of urine samples (33); more 
surprisingly the values of CPMG serum spectra are higher than Noesy serum spectra. 
Not according to the relative frequent hypercholesterolemia (34-36) in CD patients, it 
seems that lipid variations do not contribute to the metabolomic signature of celiac 
disease. Separations between the two groups are also well visible in the Figure 2.1. 
Focusing the analysis on the CPMG (Figure 2.1 A) cluster and discrimination values, it is 
noticed that only three subjects are mis-clustered and only four subjects are, then, 
mis-assigned.  
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Figure 2.1 Clustering obtained by use of PLS-
RCC method on serum CPMG (A) and NOESY 
(B) spectra, and urine NOESY (C) spectra. 
Practically the SVM method mis-classified only one subject that is correctly clustered 
by PLS-RCC method. Interestingly this subject, which belongs to the group of controls 
(HS), has a familial history of lymphoma and myeloid leukemia. Regarding the other 
three subjects, two of them are celiac classified as HS and one is a control classified as 
celiac disease affected. Both CD subjects are completely asymptomatic, they are 
detected as celiac during familial screening, while the last mis-classified HS has a 
history of thyroid carcinoma and presents low levels of folate and ferritin like a great 
part of CD subjects; moreover, during collection he assumed levothyroxine. To assess 
which resonance peaks are significantly discriminating between CD subjects and HS, 
each bucket is analyzed using both ANOVA and non-parametric analogue Kruskal-
Wallis test. Discriminating buckets are chosen on the basis of the P value, it must be 
lower  than 0.05 (for urine) and 0.01 (for serum), with applying Bonferroni correction. 
Using this kind of variance analysis many metabolites show significant differences in 
concentration between two groups (see Table 2.2 and Table 2.3). 
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Table 2.2  Metabolites that are statistically 
different in sera of CD patients with respect to 
HS (P<0.01, Bonferroni correction applied). 
 
Table 2.3 Metabolites that are statistically 
different in urine of CD patients with respect to 
HS (P<0.05, Bonferroni correction applied). 
Interestingly, it is noticed that some metabolites present in the above tables are 
involved in the same metabolic pathways. In particular the Table 2.2 data suggest an 
alteration of the glycolysis process, the metabolism of glucose. Indeed higher levels of 
glucose and lower level of pyruvate, the last product of glycolysis, are present in sera 
of CD patients than in HS. If in literature the presence of high levels of glucose in CD 
patients is reported (37), decreased pyruvate is never signalled in CD patients. 
Moreover, if the alteration of glucose is linkable to various conditions, as for example 
the up-regulation of glucose intake at the level of microvillus membrane caused by an 
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alteration of the lipid-protein ratio of the same membrane, the decreasing of pyruvate 
in sera is consistent with the reduction of glycolysis. Furthermore, this hypothesis is 
confirmed by higher levels of 3-hydroxybutyrate in sera and acetoacetate in urine of 
CD patients (Table 2.3). These two metabolites are the product of the ketonic bodies 
catabolism, a supply pathway to convert energy as in case of reduction of glycolytic 
activity. Besides, ketonic bodies catabolism also lipid β-oxidation seems to be activated 
in CD patients, reading Table 2.2 lower level of lipid (determined through their R-CH2-
CH2-CO and –C=C-CH2-C=C- signals) are present in sera. This is probably caused by i) 
activation of lipid β-oxidation to replace the lack of energy due to less efficient 
glycolysis ii) alteration in gut intake of lipids due to mal-absorption associated to villi 
atrophy. The conversion of energy through these two ways is quite less efficient than 
glycolysis and it should explain the high frequency of chronic fatigue in CD patient. 
Finally these suggestions should be confirmed by follow-up metabolites data 
expressed in Table 2.4 (see below), after 12 months of gluten-free diet all the previous 
considered metabolites return to normal levels with the exception of acetoacetate. 
Other interesting altered metabolites reported in Table 2.2 and Table 2.3 are choline 
and some aminoacids (such as asparagine, leucine, methionine, proline, valine) and, 
above all, IS (indoxyl sulfate), mHPPA (meta-HydroxyPhenylPropionic Acid) and PAG 
(PhenylAcetylGlycine). Choline and aminoacids are found to be lower: this is probably a 
direct consequence of mal-absorption by villi atrophy. The lower levels of IS, mHPPA 
and PAG are due to an alteration of gut microflora. While mHPPA is one of the several 
products of the microbiologically mediated breakdown of poliphenols (as caffeic acid) 
and the conjugate chlorogenic acid (38-39), IS is a harmful uremic toxin produced by 
the liver starting from indole. Indole is one of the products of tryptophan metabolism 
by intestinal bacteria (40). PAG is only recently attributed to gut microflora (41) and its 
contribution to the production of these metabolites has not been fully characterized 
yet (42). However, these three metabolites suggest a significant alteration of the gut 
microflora activity, that is recently indicated as one of the probable major 
environmental factor involved in the pathogenesis of CD (44). Some types of statistical 
analysis are also applied by follow-up samples. Substantially the number of these 
samples is not quite sufficient and uniform to give a clear description of what is 
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happening during the gluten-free diet period. However, as reported in Figure 2.2, after 
12 months of gluten-free diet (GFD) all samples but one are classified as belonging to 
the HS group, while after 3 and 6 months a great large number of samples remain 
classified as CD ( Figure 2.3). 
 
Figure 2.2 Predictive clustering of CPMG serum spectra of patients after 12 months of GFD 
 
Figure 2.3 Recovery percentage of CD 
patients under gluten-free diet in function 
of the months of diet. 
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Furthermore, metabolites that show a statistically significant variation between 
untreated CD patients and corresponding follow-up after 12 months of GFD, are found 
using a P value discrimination of 0.05. Obtained data are reported in Table 2.4.  
 
Table 2.4 Metabolites that significantly varies 
after 12 months of GFD. 
They confirm the previous suggestion about metabolic processes involved in celiac 
disease, indicating a return to “normality” after a few months of diet. In particular it is 
noticed a strong correlation between glucose and 3-hydroxybutyric acid levels (with r 
value of 0.93), as to indicate the restore of the glycolysis as principal pathway of 
conversion of energy. 
Conclusions and Perspectives 
This work, published in the Journal of Proteome Research and attached here in the 
proper chapter, fully shows the existence of a typical metabolomic signature for celiac 
disease, based on three components: i) mal-absorption, ii) alteration of energy 
metabolism and iii) alteration of gut microflora. In this way it also suggests to explore 
new features and to investigate some unsolved aspects of CD, such as chronic fatigue. 
Nevertheless, it is necessary to extend them to distinguish CD from other causes of 
mal-absorption, such as small intestinal bacteria overgrowth, Crohn’s disease, short 
bowel syndrome and so on; moreover, it is required to completely understand the 
capability of metabolomic to clearly highlight the presence of CD, even for peculiar 
forms of the pathology, as silent form and latent form. For the last purpose another 
study has already started with more than 100 samples of urine and serum analyzed. 
The study plainly provides a blind analysis of a significant number of samples coming 
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from subjects with various characteristics (HS, classic CD subjects, CD subjects on diet, 
latent CD subjects, silent CD subjects, subjects that suffers of other intestinal 
pathologies). These samples will be tested using as classification trial the test sets 
developed during the first study.  
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Breast Cancer 
Introduction and classification 
Breast cancer is a type of cancer that usually starts in the inner lining of the milk ducts 
or lobules. It is the second most common cancer after lung cancer worldwide, with an 
incidence of 10.4 % (calculated on both genders), and the fifth most common cause of 
cancer death (519.000 ca. deaths in the 2004, equal to 7% of all cancer deaths) (1). 
Breast cancer is about 100 times more frequent in women than in men, even if the 
rates of survival are practically equivalent. Currently four different types of 
classification exist for breast cancer. All these classifications are done on the basis of 
different criteria and serve  different purposes. These different schemes consider i) the 
type of pathology, ii) the grade of the tumor, iii) genetic and proteic expression and iv) 
the stage of tumor. 
Type of pathology : It is a classification based on histological appearance and on some 
other pathological criteria. From this point of view, the most common types of breast 
cancer are ductal carcinoma (malignant cancer in breast ducts) and invasive lobular 
carcinoma (malignant cancer in breast lobules). 
Grade of tumor : It is determined by the pathologist using a microscopy and the 
Bloom-Richardson-Elston staging system (2-3). With the microscopy it is assigned a 
score ranging from 1 to 3 to the three followed features: i) percentage of tumor with 
normal ducts, ii) number of observable mitotic figures and iii) characteristic of cell 
nuclei. Therefore, the final score will be included between 3 (well differentiated, best 
prognosis) and 9 (poorly differentiated, worst prognosis). In details, tumor with scores 
between 3 and 5 are grade 1, between 6 and 7 are grade 2 and between 8 and 9 are 
grade 3.  
Genetic and Proteic Expression : This test is usually done by immunohistochemistry. 
The breast cancer cells are tested for expression of some genes, as estrogen receptor 
(ER) and progesterone receptor (PR), and of some proteins, as human epidermial 
growth factor receptor 2  (HER2). 
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Stage of tumor : It is used the so-called classification of malignant tumors (TNM). TNM 
classification gives a code of a tumor constituted by a letter, that can be “T”, “N” or 
“M”, and respectively means Tumor, lymph Node and Metastases. The letter is 
followed by a numeric or alphanumeric code to substantially indicate some 
parameters of tumor as invasiveness, dimension, presence of tumor cells outside the 
breast, number, size and location of breast cells deposits in lymph node.  
Finally, these are not all possible classifications, for instance it is possible to do a 
classification based on the presence of inflammatory states (4);  moreover, some of 
these parameters can be significantly modified  over time.   
Etiology and epidemiology 
Although the first work on the epidemiology and etiology of breast cancer was 
published in 1926 by Janet E. Lane-Claypon for British Ministry of Health, at present it 
is not possible to establish correctly the epidemiological risk factor and etiology for 
every type of breast cancer. Indeed epidemiological research allows us to identify 
factor risks for a population, as incidence and prevalence, but does not give 
information about the single individual. At the same time about 5% of new breast 
cancer are attributable to hereditary factors, while the etiology of the other 95% is 
unknown (5). Breast cancer, like other forms of cancer, is considered to result from 
multiple environmental and hereditary factors. Moreover, a series of primary risk 
factors are identified as gender (6), age, hormones (7), a high-fat diet (8), alcohol 
intake (9), obesity, but only a small increase in breast cancer frequency is attributed in 
this study to these factors, and these studies are often not well randomized. 
Furthermore, the expression of two genes, called BRCA1 and BRCA2, is associated with 
an increase of about 30-40% of breast and ovarian cancer risk (10). Finally, personal 
and familial history of breast cancer significantly increases the risk of this pathology, 
while, for instance, some races, as Latina, Asian or Afroamerican are less subject to this  
pathology than Caucasian. 
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Clinical manifestations and signs of breast cancer 
It is considered that, in about 80% of cases (1), breast cancer is discovered by the 
patients themselves when they find a lump that feels different from the surrounding 
breast tissue. Sometimes the lumps, especially if they are very small are discovered 
through a mammography. Moreover, the presence of a lump in the armpits (lymph 
nodes) is also a possible symptom of breast cancer. Obviously many other signs may be 
included,  as changes in size or shape, skin dimpling, nipple inversion. Pain (called 
mastodynia) is another possible symptom but it is not characteristic. Indeed, it is 
possible to have it in many other breast pathologies such as mastitis and fibro-
adenoma. When breast cancer cells invade the lymphatic dermals, that are small 
vessels in the skin of breast, its presentation can resemble skin inflammation and thus 
is known as inflammatory breast cancer. Symptoms of inflammatory breast cancer 
include pain, swelling, warmth and redness throughout the breast. Another reported 
symptom complex of breast cancer is Paget’s disease. This is a syndrome that presents 
eczematoid skin changes such as redness and mild flaking of the nipple skin. As Paget's 
advances, symptoms may include itching, increased sensitivity, burning, and pain. 
There may also be discharge from the nipple. Approximately half of women diagnosed 
with Paget's also have a lump in the breast (11). Furthermore, when breast cancer is 
manifest in the metastatic form a great number of new symptoms  also appear, which 
depend on the location of metastasis. Common sites of metastasis include bone, liver, 
lung and brain (12). Unexplained weight loss can occasionally herald an occult breast 
cancer, often associated to very frequent symptoms as fever and chills. Bone or joint 
pains can sometimes be manifestations of metastatic breast cancer, as some 
neurological symptoms. These symptoms are "non-specific", meaning they can also be 
manifestations of many other illnesses. However, the presence of one or more of 
these symptoms have to be seriously considered by the person,  because of the 
possibility of an underlying breast cancer at almost any age. 
Diagnosis and Therapeutics 
The most common used screening method for diagnosis of breast cancer is a 
combination of X-ray mammography and clinical breast exam. In women at higher risk 
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than normal, such as those with a strong family history of cancer, additional tools may 
include genetic testing or breast Magnetic Resonance Imaging (MRI). Breast self-
examination was a form of screening that was heavily advocated in the past, but  
several large studies have shown that it does not have a survival benefit for women 
and often causes considerably anxiety. This is due to the fact that breast cancer can be 
detected at a relatively advanced stage operating in this way, whereas other methods 
push to identify the cancer at an earlier stage where curative treatment is more 
possible. X-ray mammography uses x-rays to examine the breast for any 
uncharacteristic masses or lumps. Regular mammograms are recommended in several 
countries in women over a certain age as a screening tool. Genetic testing for breast 
cancer typically involves testing for mutations in the BRCA genes. This is not generally 
a recommended technique except for those at elevated risk of breast cancer. While 
previously discussed screening techniques are useful in determining the possibility of 
cancer, a further testing is necessary to confirm whether a lump detected on screening 
is cancer or other, like a simple cyst. The common diagnosis is elaborated after a 
"triple test" of clinical breast examination led  by a trained specialist. This triple test 
comprises mammography, fine needle aspiration and cytology (FNAC). Both 
mammography and clinical breast exams, also used for screening, can indicate an 
approximate likelihood that a lump is cancer, and may also identify any other lesions, 
while FNAC extracts a small portion of fluid from the lump. If the fluid is clear the 
cancer is highly probably absent, while if there is presence of blood in the fluid, it is 
necessary a microscope inspection to check the presence of cancer cells. These three 
tools can be used to diagnose breast cancer with a good degree of accuracy. Another 
useful option is biopsy, which  consists in the removal of either part or entire lump. As 
for other tumors, the mainstay of breast cancer treatment is surgery when it is 
localized, with possible adjuvant hormonal therapy (with tamoxifen or an aromatase 
inhibitor), chemotherapy, and/or radiotherapy.  Depending on clinical criteria (age, 
type of cancer, size, metastasis) patients are roughly divided into high risk and low risk 
cases, with each risk category following different rules for therapy. 
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Metabolomic study of Breast Cancer 
Aim of the work 
The natural aim of every work which investigates breast or other types of cancer, is the 
improvement of the knowledge of both pathologies and exploitable clinical therapies. 
Metabonomics, being a science that provides a dynamic portrait of metabolic status, 
can be very useful in these directions. Particularly the improvement of the prediction 
of clinical outcomes is necessary to have a better approach to breast cancer, 
individualize the therapy and reduce the high side effects associated to it. For these 
purposes,  the attention is focused on the possibility to discriminate i) pre-operative 
not-metastatic breast cancer subjects ii) post-operative not-metastatic breast cancer 
subjects and iii) post-operative metastatic breast cancer subjects, by relying on the 
metabonomic analysis of the serum. Moreover, an important goal is to check the 
capability of metabonomics to single out the presence of micrometastasis in an 
organism. Indeed, in the treatment of early breast cancer, a critical issue is the 
identification of which individuals can benefit from adjuvant intervention. As 
mentioned above, the patients are divided into two groups (high and low risk) and 
their therapy is decided starting from this classification. However, the risk is often 
under- or over-estimate and, as a consequence, the applied therapy is not completely 
corrected and appropriated. One, and probably the most, important cause of this mis-
assignment is the existence of unpredicted micrometastasis in the host. The study of 
micrometastasis is a step not easily solvable. In this work it is hypothesized  that a 
metabonomic fingerprint of the micrometastasis exists and to check this metabonomic 
risk, data are compared with 10-year mortality rates data obtained from the use of 
Adjuvant!online (13) software.  
Collected serum samples are divided into three classes: i) 44 pre-operative early breast 
cancer ii) 98 post-operative early breast cancer (44 as the same of pre-operative, 45 
new recruited) iii) 51 metastatic breast cancer. For early breast cancer patients the 
mean time between pre-operative collection and surgery is 16 days (range 2:40), while 
for post-operative is 33 days (range 16-55). 
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Results and Discussion 
 
A clusterization between early pre-operative and metastatic subjects was obtained for 
both cpmg and serum spectra using O-PLS (Figure 3.1 A e 3.1 B). Looking at the figure 
it is noticeable the clearly separation between the two groups revealing the existence 
of a metabonomic fingerprint for metastatic pathology with respect to not-metastatic. 
After this process, a double cross validation scheme is applied to single out the correct 
value of prediction of defined statistical approach. A great number of individuals are 
correctly classified, whilst some cases of misclassification exist. Right percentage of 
recognition for CPMG are 75% of sensitivity, 69% of specificity and a global predictive 
accuracy of 72%. Similar values are obtained using NOESY1D, sensitivity of 77%, 
specificity of 68% and predictive accuracy of 73%. Through the application of Wilcoxon 
test with Bonferroni correction, some metabolites that are significantly discriminating 
between the two classes (p value < 0.05) are identified. Indeed metastatic subjects are 
characterized by higher value of glucose and of some aminoacids as phenylalanine, 
proline, lysine and N-acetyl cysteine and by lower value of many lipidic signals that are 
present in unfiltered noesy spectra. 
Clusterization showed in Figure 3.1 suggests that some pre-operative samples present 
very similar characteristic to metastatic samples. In order to better understand the 
cause of these misclassification, a factor of risk, called “Metabolomic risk” is assigned 
to every not-metastatic sample. The value of each Metabolomic risk is assigned 
measuring the Euclidean distance of each dot from the centre of metastatic cluster. 
Obviously, it is supposed that samples that have a higher distance from metastatic 
center have less metastatic characteristic  and, therefore, they have a lower value of 
risk. Practically, the shorter is the distance the higher is the risk, and vice versa. 
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Figure 3.1 O-PLS of pre-operative (N=44) and metastatic 
(N=51) patients showing near complete separation of 
patient groups; CPMG (A) and NOESY1D (B) techniques. 
The next step is to compare the Metabolomic risk with the established risk by using 
Adjuvant!online software. Adjuvant!online is a free software that is very useful to 
predict the risk of relapses and mortality associated to a breast tumor in not-operated 
subjects, if they are not treated;  moreover, the software also values the reduction of 
the risk in case of specific therapies. Parameters used by software are related to form 
and type of tumor, as size, hormonal receptor (ER) status, lymph node involvement 
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(14), but also to some patient characteristics, as age, diet, used drugs In Figure 3.2  the 
comparison between metabolomic risk and 10-year mortality by Adjuvant!online is 
reported. 
 
Figure 3.2 Correlation between 10-year breast cancer mortality 
estimated by Adjuvant!online (A) and Metabolomic risk (M) for 
pre-operative patients (pts). 
A clear relationship between the two established risks does not seem to be present at 
a first exam of the previous figure. Particularly,  it is noticeable that there is a 
significant discordance for three samples (present in the right extreme limit) that are 
classified as having a very high metabolomic risk whilst they do not seem to be a risk 
for adjuvant. The percentage value of concordance is about 48% for both metabolomic 
high risk and metabolomic low risk. To explain these data,  the best possible 
assumption is related to the presence of micrometastasis in some breast cancer hosts. 
Indeed micrometastasis are not considered in calculation of risk by Adjuvant!. 
Therefore, pre-operative patients that have a metabonomic fingerprint similar to 
metastatic subjects and, as a consequence, are the nearest to metastatic cluster, could 
have residual micrometastasis in their own bodies. To confirm these hypotheses, it is 
decided to use post-operative serum samples coming from same subjects as validation 
test set, in order to minimize inter-individual variation. The same methods of 
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clusterization and classification for pre-operative specimen are also used in this case 
leading to following results (see Figure 3.3).   
 
Figure 3.3 Impact of surgical removal of primary tumor on 
metabolomic risk 
In the above figures,  each bar represents the change of the metabonomic risk in pre- 
and post-operative samples; the longer the bar, the higher the variation of risk. In 
details i) 100% (11 of 11) of previously classified as lowa/lowm subjects remain in  the 
same class of risk, ii) 92% (9 of 12) lowa/highm show a risk reduction, iii) 80% (8 of 10) 
higha/highm have a reduction of metabonomic risk after surgery, iv) 36% ca (4 of 11) of 
higha/lowm  show interestingly a sizeable increase of metabonomic risk, whilst the 
others remain in the same class of risk. This last trend is the most interesting to 
analyze, because it seems to apparently be contrasting logical supposition. Indeed if a 
not-metastatic tumor is removed from the hosts, the risk of recidive and/or death 
should decrease.  Actually,  it is still suggested in literature that the surgical removal of 
a primary tumor could increase the risk of a future disease (15-17). The stress that is 
associated to a surgery, and that can cause both immunosuppression and proliferation 
of growth factors, can significantly trigger the possibility of tumor growth (18-19).  
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Conclusions and Perspectives 
In this work it is showed that a metabonomic fingerprint seems to exist for metastatic 
patients and it is observable analyzing serum samples. The differences between 
metastatic and early breast cancer patients are noticeable in both pre-operative and 
post-operative samples (i.e. coming from the same subject). Actually the collected 
biostatistical data are not very high in term of accuracy (about 70%). This is also 
probably due to great inter-variability. To overcome this problem it is necessary to 
collect more than one sample from the same subject in a short period of time. 
However, a definition of metabonomic risk, as percentage probability of 10-years 
death risk after surgery, is defined and compared with Adjuvant!online data. 
Metabonomic risks are partially in agreement with Adjuvant!online risk, but there are 
also significant differences that are attributed to the possible  existence of 
micrometastatis (not identifiable by Adjuvant!online). The only and better way to 
confirm these suggestions is to repeat the study in a class of subjects which is also 
donating follow- up samples, in order to highlight the effects of a possible progression 
of the pathology. Another important approach can be the analysis of tissues of breast 
cancer. The analyses of tissue is still  used in metabonomics and it has led to the 
significant results of suggesting sarcosine (20) as a possible biomarker of prostate 
cancer progression. Similarly, an identical approach is useful in order to completely 
understand the metabolism of breast cancer and also to study in details both the role 
of phenylalanine in tumor progression and the importance of its pathways in the onset 
of breast cancer and, moreover, in progression to metastasis. 
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Background 
Since their birth, metabolomics has showed a great potential in various research areas. 
In particular the relevance of metabolomics can be greatly enhanced by the 
determination of the existence of a metabolic phenotype, typical for each subject. 
Differences in experimental metabolic profiles due to genetic strain differences in 
animal models have been observed, leading to the suggestion that each individual or 
group of individuals may be characterized by a different metabotype, defined as “the 
multiparametric description of an organism in a given physiological state based on 
metabolomic data” (1). The availability of a characteristic metabotype of an individual 
could be fundamental in many fields as nutrigenomics (2,3), in evaluation of drug 
efficacy, in pharmacometabolomics (4), and in studies of personalized nutrition aimed 
at maintaining metabolic health and avoiding loss of homeostasis or correcting 
homeostasis dysregulations. Of course, a fundamental condition of metabotypes is 
their stability over time. A major problem is that the experimental metabolic profile is 
influenced not only by the genotype but also by age, lifestyle, environmental factors, 
nutritional status, assumption of drugs, and by other metabolites from symbiotic 
organisms, as gut microflora (5-7). Consequently, changes in the metabolic profile of 
biologically complex organisms (as humans) in response to pathological stimuli may be 
difficult to distinguish from normal physiological variations. Despite these factors, the 
experimental evidence of the existence of a metabolic phenotype is recently collected 
(8), assessing the influence of possible perturbing factors on the metabolic profiles and 
minimizing them in order to eliminate noise due to random daily variation. Indeed the 
approach used for the determination of the metabotypes counts on the NMR analysis 
of multiple urine samples (40 for each individual) taken in quite consecutive days 
(about 2-3 months) from 22 healthy subjects. Each  of these subjects avoids alcohol 
and drug intake the day before the collection, and, moreover, fills a complete dietary 
sheet in order to better determine changes due to food behaviour. In this way,  it is 
obtained for the first time a natural, stable, and invariant metabolic profile that is 
typical for a given subject, even if not necessarily unique. As  hypothesized, the 
identification of a characteristic individual fingerprint is very useful because it may 
allow the researchers to i) better plan personalized therapy and nutrition, ii) perform 
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studies of pharmacometabolomics to better predict and assess drug efficacy and 
toxicity, iii) follow phenotype changes as a function of disease progression, possibly 
leading to earlier diagnosis and prognosis, iv) perform cost-effective screenings on 
large human populations and v) address how possible long-term changes may be 
related to aging. The fingerprint is assessed to be stable only in a short period. 
Aim of the work 
The discovery of the existence of a stable individual human phenotype in a short 
period of time (about 2-3 months) is clearly an important improvement for 
metabolomics (8). At the same time it is necessary to unravel the behaviour of the 
metabotypes in a more extensive time period, in order to completely help researchers 
in all above mentioned fields and, especially, for medical application. To solve this goal 
11 subjects of the project called MetRef1 (8) are recruited again after 2 years, entering 
in the MetRef2 project, and 4 of them are recruited one more time 1 year later, 
entering in the MetRef3 project. Nine healthy individuals, not present in MetRef1, are 
recruited after 2 years of MetRef1 together with the other 11 subjects. These new 
recruited subjects result  to be useful to further extend the analyzed metabotypes and 
try to define the possible saturation of the metabolic space, in order to highlight the 
eventual presence of shared metabotypes in  two or more subjects. In this way the 
project MetRef2 is constituted by 20 individuals (9 males, 11 females), aging  25-55, 
donating 40 urine samples (first in the morning, pre-prandial) collected over a period 
of about 3 months. While MetRef3 is constituted only by 40 samples donated by 4 
subjects recruited for the third time (see Figure 4.1). 
Moreover, there are some singularities in the new collections that, although not 
statistically relevant, can contribute to better understand environmental and genetic 
contributions to the definition of the individual metabolic phenotypes. As it is 
noticeable in Figure 4.1, two new recruited subjects are homozygous twins (indicated 
with TA and TB codes), while other two subjects (BU and BV) are father and son. 
Moreover, some subjects that are donating in more than one project quite drastically 
change their lifestyle, as BC, who, during the two collections, moved from Italy 
(MetRef1) to Spain (MetRef2), varying the diet, and AR, who quitted smoking. 
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      Figure 4.1 Collection scheme of the three MetRef projects.. 
Results and Discussion 
To correctly define the metabolic space, it is necessary to start from the data published 
about the first MetRef work (8). These results are represented in Figure 4.2. 
 
Figure 4.2  Dendrogram relative to cluster analysis on the 21-
dimensional PCA/CA subspace for the 22 subjects of the MetRef1 
collection. 
In the dendrogram, each vertical bar is a single spectrum while each horizontal bar 
represents the inter-sampling distances for all spectra in a statistical space defined 
through a PCA/CA analysis. Moreover, the colours obviously highlight the spectra 
belonging to an individual (as reported in x axis), and therefore the black coloured bars 
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result to be a representation of the interindividual distances; practically every fork 
gives a measure of the metabolic affinity between the individuals. These 
representation is very useful in this case since it is totally impossible to  perform the 21 
dimensional space of the system. However, it is clearly visible that all subjects present 
a typical metabotype, there are not overlaps among all coloured lines by each 
individual. Furthermore, these trends are confirmed through a predictive analysis using 
the single vote classification: the mean value is 99.7% for MetRef1 collection (see 
Table 4.1). The same identical analysis is done on the 20 individuals of the MetRef2 
projects giving very similar results both as dendrogram visualization (Figure 4.3) and as 
percentage of recognition that results to have a mean of about 99.6% (Table 4.1). 
 
Figure 4.3  Dendrograms relative to cluster analysis on the 19-
dimensional PCA/CA subspace for the 20 subjects of MetRef2 collection. 
These results confirm the robustness of the method still used in  the first work. 
Moreover, analogous results, as dendrograms (Figure 4.4) and recognition values 
(Table 4.1), are obtained pooling together all 31 individuals of the MetRef1 and 
MetRef2 collection (clearly for the subjects that are participating to both collections 
the analyzed spectra are about 80 for each one). All these data confirm the existence 
of various individual metabolic phenotypes and suggest that the number of these are 
higher than 20 and not yet defined. Thus the metabolic space is probably distant to be 
satured and this opens significant perspective in fields as biology and medicine.  
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Figure 4.4  Dendrogram relative to cluster analysis on the 30-dimensional 
PCA/CA subspace for the 31 different subjects of both MetRef 1 and MetRef2 
collections. 
 
Table 4.1  The individual single vote scores, respectively for a) MetRef1 collection, b) 
MetRef2 collection, c) the 31 Different Donors from both collections, d) All 46 
Pseudodonors. 
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One fundamental step in the development of this work is the identification of time 
stability of the metabotypes. In order to satisfy this request the spectra of the same 
individuals that are present in different collections (11 for MetRef1 and MetRef2, 4 for 
MetRef3) are used in a single vote classification as both training and test set (see Table 
4.2) 
 
Table 4.2  Single vote classification. 
Different collections are used as training 
and test sets. 
As it is noticeable, the means are high and substantially similar, even if, using MetRef3 
as training set and MetRef2 as test set, the value is slightly lower. These high 
percentages reported in the previous table demonstrate that the metabotypes 
substantially remain stable in a time scale of about two-three years and this is a 
significant basis to the medical implication of the metabotypes. Indeed this justifies 
that drugs are metabolized in different ways by different subjects and, therefore, they 
may have different both positive and adverse effects. Moreover, these findings suggest 
the necessity to develop all medical therapies in a personal way or, even better, in 
different ways according to various existing metabotypes. In details it is possible to 
note in the previous table that some individuals, as, for instance AS, present value of 
recognition slightly  lower than others. To better understand what the cause of this 
result is,  it is possible to see the distance colour-coded matrix for all individuals that 
participate in at least two collections reported in Figure 4.5. The dark blue diagonal 
represents the spectra of all individuals in the same collection, that are clearly 
associated to the lowest distances (dark blue colour code), while the other four light 
blue square diagonals are associated to the spectrum of the same individual in 
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different collections to demonstrate that there is a partial confusion between various 
collections due to a relative stability of the metabotypes over time. For the individual 
AS the light blue squares in these four diagonals are relative darker than for the other 
subjects, to highlight shortest distances between collections that cause a major 
confusion (see also Table 4.1 column d). In conclusion AS has the most stable 
metabotypes in a short time scale. 
 
Figure 4.5  Distances in metabolic space  
for all individuals that participated 
 in at least two collections. 
Same results are also showed by the dendrogram in Figure 4.6, which is obtained 
considering each set of 40 spectra coming from the same individuals that participated 
to all three collections as different and not correlated pseudoindividuals.  
This approach confirms the stability of the metabotypes. Indeed the same 
pseudoindividuals are clustered together and in some cases it is presented also a 
superimposition as, for instance, it has been  highlighted for AS with Figure 4.5. Some 
considerations about the environmental and genetic contributions to metabotypes can 
be done by examining the previous figure. In particular TA and TB (homozygous twins) 
present  the shortest fork in dendrogram 4.4, followed by BU and BV that are father 
and son, indicating the presence of a genomic component. Furthermore, in the new 
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dendrogram the fork between TA and TB is one of the shortest and it is comparable 
with the forks among same pseudoindividuals. Practically TA and TB show a behaviour 
analogous to the same individuals in different collections in the dendrogram. These 
findings are also confirmed by the use of a single vote classification; the few 
misdiagnosed samples for TA and TB are assigned to one another, not casually 
assigned to other subjects as it happens for all individuals. 
 
Figure 4.6  Dendrogram relative to cluster analysis on the 45-
dimensional PCA/CA subspace for all the 46 different 
pseudoindividuals of all three collections.  
 
Finally it is necessary to make a consideration on the variability of the spectra. Even in 
this work it is clearly shown the time stability of the metabotypes, the detailed visual 
analysis of the spectra reveals some differences between various collections. These 
differences are classified as “spikes”, “waves” and “jumps” and they seem principally 
due to diet effects. In particular, i) spikes are signals that appear in a single spectrum  
having marked  differences in intensity between preceding and following days, ii) 
waves are signals that have a more gradual variation in intensity but  persist for more 
days, iii) jumps are signals that markedly appear in a collection  as spikes but they 
remain practically unchanged for all the collection and, sometimes, they are carried to 
next collection and are reversible. Spikes are principally due to particular food intake, 
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for instance the peak of TMAO (TriMethylAmine-N-Oxide) (9) clearly appears in spectra 
of urine collected the day after a fish diet intake, as well mannitol appears after 
chewing gum intake. At the same time many other events can cause a spike, as very 
intense physical activity (lactate), drug consumption (paracetamol-O-glucoronide), 
excessive alcohol intake (ethanol). Moreover, it is present in a BF subject a case of 
“anti-spike”, due to the disappearance of citrate signals, probably associated to a 
kidney metal complexation. Nevertheless, a particular diet is one of the causes of some 
jumps, in particular for individual AW it is observed a jump for xanthosine (10) due to 
an excessive meat consumption during a period of several days. A great number of 
jumps and waves are really due to the modification of gut microflora. It is noted that 
the peaks involved in waves and jumps are principally due to metabolites as hippurate, 
meta-hydroxyphenylpropionate, formate and phenylacetylglycine that are usually 
products of the metabolism of intestinal bacteria (11-15) and, therefore, linkable to 
activity variations of gut microflora. This last consideration leads us to consider the 
individual metabolic phenotypes as a metagenomic entity strongly affected by host 
genotype, environmental factors and gut microbiome. 
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Aim of the work 
This epidemiological study on healthy subjects was born with the aim to better 
understand the complex biological mechanisms that occur in living organisms. In order 
to reach this goal it has been decided to analyze a great number of EDTA-plasma 
samples (not fewer than 1000), that are collected from healthy blood donors in the 
Hospital of Pistoia. Due to this high number of samples, the project is quite widespread 
and complex, and therefore some sub-projects are identified, with specific goals to 
reach:  
1.Relationship study between altered blood parameters and metabolic fingerprints 
(Altered Blood Parameters) . 
2.Relationship study between peculiar behaviours of sample donors and metabolic 
fingerprints (Peculiar Behaviours). 
3.Relationship study between SNPs genetic polymorphisms and metabolic fingerprints 
(SNPs). 
Altered Blood Parameters 
A considerable amount  of information is present in plasma NMR spectra. In particular, 
some molecules have peaks arising in plasma spectra, such as cholesterol, LDL, HDL, 
glucose and so on.  These molecules are usually considered as “healthy state signals” 
for each individual, and for them it is given a range of confidence associated to the 
normal condition. However, they are not sufficient to completely define both healthy 
status and percentage of risk of cardiovascular pathologies onset. Therefore, current 
European guidelines for the prevention of coronary heart diseases recommend to base 
any intervention on the evaluation of total risk (1). In order to estimate such a risk, 
several predictive equations have been developed in the last decade (2-3). Possibly 
also metabolomics can be used as a method to define some of these factors of risk, so  
metabolomics spectra contain all the possible metabolic information that is present in 
blood. In order to check this hypothesis, a first step consists in the analysis of the 
relationship existing between the previous value determined by the standard method 
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of analysis and the same value predicted by the metabolomics statistical analysis. 
Practically, it is necessary to determine the existence of any kind of correlation 
between the first ones (that can be called true values for simplicity) and the second 
ones (that are predicted values), in order to verify the real capability of metabolomics 
to highlight standard blood values. The second step is the real definition of a 
metabolomics risk. Some other parameters, also associated with individual behaviour, 
can be considered to solve this goal. 
Peculiar Behaviours 
It is generally assessed that the healthy state of an organism is strictly related to the 
life style, besides genetic factors. Therefore, some of the  so-called “proper” 
behaviours have been identified as well as “not-proper” ones. For instance, a balanced 
diet and a steady physical activity are usually considered as a healthy pattern  for an 
individual. In the same way some habits are considered risky or harmful, such as 
smoking cigarettes, high alcohol intake and so on. Many of these “not-proper” 
behaviours are largely widespread in modern society, especially in the most developed 
countries. Thus their impact on the individual metabolism, and therefore, on the 
individual healthy state  have been already studied, see for instance the studies on the 
increment of risk percentage of lung cancer in smokers. There has been an increasing 
interest in the application of the metabonomic approach also to these fields recently 
(4-6). Indeed there is obviously a great advantage in the application of the 
metabonomic approach to the exam of the “un-proper” life styles. It is clearly possible 
to supervise the contemporaneous alterations of various metabolic pathways. In this 
way it is not only given a complete metabolic definition of all specific metabolic 
alterations due, for instance, to smoke but it is also possible to investigate how 
individual metabotypes can react to this and be able to define a possible percentage of 
risks of the onset of correlated pathologies. Naturally this step is strictly related to the 
previous one (altered blood parameters);  most of these “not-proper” behaviours 
cause a significant alteration of blood parameters before the pathology. 
SNPs 
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The last goal is to discover a relationship between genome and metabolome. It is 
assessed how the genome is one of the principal causes of the healthy state of a 
subject. Moreover, some gene mutations can cause serious pathologies that are not 
compatible with life in many cases.  
Nevertheless, some other mutations are not  strictly correlated with pathologies. Some 
of them are called SNPs, or Single Nucleotide Polymorphism, and generally are  
responsible for different enzymes (isoforms) in different subjects. Basically a SNP is a 
single variation in DNA sequence generally due to the changing of one of the 
nucleotides. In details SNPs may be changed (substitution), removed (deletion) or 
added (insertion) to a polynucleotide sequence. When there is this kind of 
modification, two different alleles exist for a gene and almost all common SNPs have 
only two alleles. It is supposed that these single variations in the DNA can affect the 
way humans develop diseases and respond to pathogens, chemicals, drugs, vaccines, 
and other agents. SNPs are also thought to be key enablers in realizing the concept of 
personalized medicine (7). It is noted that the existence of SNPs is relatively common 
for genes coding for enzymes involved in glucidic (8) and lipidic (9-10) metabolism. 
Therefore, the polymorphisms that will be considered in these projects are associated 
to genes with an important metabolic role. In details 4 genes are selected: i) PPARγ2 
(Peronisome Profiletor Activated Receptor γ2 ii) LIPC (hepatic LIPase gene) iii) FADS1 
(Fatty Acid DeSaturase) iv) SREBP-1c (Sterol Regulatory Element Binding Protein 1c).   
PPARγ2 is a gene involved in the metabolism of lipids and glucose. The most common 
polymorphism is Pro12Pro, while the other is Pro12Ala. In a recent study it is noted 
that Pro12Ala polymorphism is associated with a diminution of activity of the hepatic 
receptor for the uptake of glucose and a higher sensibility to insuline (11). 
LIPC is involved in HDL metabolism. The selected polymorphisms for the gene are 
rs12593008, rs261342 and rs4775041. It seems that their expression is associated with 
a low level of HDL, especially in women (9). 
FADS1 is related to the enzyme Delta-5-Desaturase, that plays a fundamental role in 
the fatty acids metabolism. Indeed it is the responsible for the desaturation of acilic 
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chains of fatty acids. Two different polymorphisms are selected: rs174548 and 
rs3834458. The first one seems to be associated with level variations of HDL, LDL, and 
free cholesterol in serum (10). The second one seems to induce the increasing of the 
selected substrates for the enzyme (12). 
SREBP-1c is a gene that codifies for an important transcription factor of both lipidic 
and glucidic metabolism. The selected polymorphisms are rs2297508 and rs11868035. 
They are associated with type 2 diabetes (13) and LDL altered levels (8). 
Partial Results and Perspectives 
Preliminary results are obtained in a widespread number of blood samples, even if not 
definitive. More than 800  samples  are collected and analyzed (809). All these samples 
are EDTA-plasma. At the same time some important clinical data are collected from 
the recruited donors. These important data are anonymized for ethical reasons. Thus 
for  every sample (and therefore every donor), a few items of  information are present 
such as gender, smoke and drug intake, blood pressure, but also glycemia, cholesterol 
and triglicerides. Moreover, also LDL and HDL values are present for a lower number of 
samples/subjects (about 200). Initially it is decided to start with a simple classification 
of samples based on some of these classical blood parameters such as cholesterol, 
glycemia, LDL, HDL and ratio cholesterol-HDL. The last one is obviously easily derivable 
from the other data and it is an important blood parameter; it explains the ratio 
between the so-called “worst-cholesterol” and the so-called “good-cholesterol”. 
Therefore, if this ratio is not high, the subject does not have theoretically any risk of 
onset of cardiovascular disease even if  cholesterol level is higher than normal. In order 
to perform the first preliminary statistical analysis, it is decided to constitute two 
classes of samples/subjects based on each  of these blood parameters. For instance, 
the two classes of samples for glycemia parameter are formed with the following 
criterium: they contain the 10 per cent of samples having respectively the low values 
and the high values of the parameter (tails). All classes are correctly divided, see Table 
5.1. This is important for many reasons. First of all, it is checked the quality of 
metabolomic analysis of collected samples and, furthermore, it is demonstrated the 
metabolomic skill to clearly highlight specific alterations of important blood 
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parameters, even if they are not out of classical “range of normality”: for instance, LDL 
normal values have to be comprised between  70 and 180 mg per 100 mL, but the 
chosen classes present respectively samples with value of LDL lower than 110 (and not 
70) and higher than 140 (and not 180), and, therefore, subjects that are not defined at 
risk in a classical way are present in the analysis too and they are separated on the 
basis of their metabolomic profile. 
 
  CPMG Spectra Noesy Spectra 
  % Correct % Wrong Accuracy % Correct % Wrong Accuracy 
HIGH (> 105)
* 
94.78% 5.22% 88.13% 11.87% 
Glycemia 
LOW (< 78) 85.97% 14.03% 
90.18% 
88.32% 11.68% 
86.99% 
HIGH (>255) 96.84% 3.16% 94.64% 5.36% 
Cholesterol 
LOW (< 160) 98.32% 1.68% 
96.52% 
96.43% 3.57% 
95.95% 
HIGH (> 140) 92.51% 7.49% 96.10% 3.90% 
LDL 
LOW (< 110) 89.24% 10.76% 
90.72% 
95.74% 4.26% 
95.36% 
HIGH (> 70) 91.58% 8.42% 92.15% 7.85% 
HDL 
LOW (< 39) 92.46% 7.54% 
91.88% 
92.92% 7.08% 
92.50% 
HIGH (> 164) 95.38% 4.62% 94.96% 5.04% 
Triglicerides 
LOW (< 51) 96.54% 3.46% 
96.45% 
97.11% 2.89% 
96.42% 
HIGH (> 4.49) 92.35% 7.65% 95.18% 4.82% 
Chol./HDL 
LOW (<3.51) 95.21% 4.79% 
93.78% 
98.39% 1.61% 
96.41% 
* = each value is expressed in mg/100 mL with exception of Chol./HDL that is a ratio 
Table 5.1 : SVM classification of samples based on PLS-CA scores 
What happens for LDL, also happens for all the other considered parameters. Starting 
from these findings, a second level of analysis is to clearly identify the signals 
responsible for these correct classifications. Obviously, the principal candidates are the 
signals due to the same parameters which are selected as classifiers. Indeed it is 
normal to expect that the principal cause of separation is glucose signal in case of 
glycemia classes, and so on. Moreover, it is also possible for some other signals to be  
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quite differently represented in each of the two classes of spectra. This supposition is 
also suggested by the fact that different lipidic classes (as high LDL/low LDL such as 
high cholesterol/ low cholesterol) are correctly classified also taking into account 
CPMG spectra, that do not have a great contribution of lipid signals. This finding 
suggests that probably other signals and, therefore, other metabolites are involved in 
the classification of the two classes. Before trying to evaluate which  these metabolites 
are, another interesting test can be carried out. The samples which have been 
considered for glycemia are re-classified again in the same classes as before taking off 
glucose signals. Basically,  it has been tried to demonstrate that subjects with low 
value of glycemia are significantly metabolomic different from subjects with high value 
of glycemia, even if the glucose and other carbohydrates signals are cutting off. 
   CPMG Spectra Noesy Spectra 
    % Correct % Wrong Accuracy % Correct % Wrong Accuracy 
HIGH (> 105)
* 
81.72% 18.28% 81.80% 18.20% 
Glicemia     
(No Glucose) 
LOW (< 78) 84.55% 15.45% 
82.83% 
82.17% 17.83% 
81.96% 
*= mg/100 mL 
Table 5.2 : Classification of samples basing on glycemia (glucose peaks cut off). 
The quite high value of correct classification obtained, more than 80% (Table 5.2), 
definitively suggests that specific alterations of metabolites different from glucose are 
present between the two glycemia classes and, thus, the metabolism of a low glycemia 
subject is completely different from a high glycemia subject. The identification of these 
metabolites is the following step in order to highlight which metabolic pathways are 
altered by high value (or low value) of glycemia, rather than cholesterol, LDL and so on. 
A third approach has been used to investigate the data, starting from previous results. 
Indeed, the finding of a strict relationship between the considered tails of each 
parameter (10% high and low for each one) and metabonomic profiles of the same 
samples leads to have the same relationship for each value of each parameter, even if 
not comprised in the previously taken tails. Practically it is tried to check if a linear 
regression between the value of parameters coming from classical blood analysis and 
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the value of the same parameters determined by using multivariate statistical analysis 
on metabolomic data (PLS-CA scores) exists. As it is possible to see in the Table 5.3, 
these relationships exist for all considered parameters (I. E., glycemia, cholesterol and 
triglicerides are not yet analyzed). The first conclusion that can be done is that 
metabolomics could be used as predictive tool of these blood values. Clearly this is an 
important finding, even if the used classical methods are probably more accurate and, 
above all, are cheaper and easily applicable. 
 
 
CPMG 
Spectra 
Noesy 
Spectra 
LDL 0,8374 0,8803 
HDL 0,8297 0,8130 
Chol./HDL 0,8577 0,8824 
  
Table 5.3 : R
2
 for correlation between predicted values (NMR 
metabolomics) and true values (classical blood analysis). 
However, the existence of this relationship suggests the possibility to define various 
metabotypes basing on these parameters, but also on other ones, such as BMI, smoke 
intake and so on. These metabotypes could be related with the risk of onset of 
cardiovascular disease and, therefore, lead to the development of an innovative 
strategy to define the risk in subjects that have, or seem to have, all classical blood 
parameters inside the normal values of confidence. In order to do this it will be 
necessary: i) to check the “presence” of all these clinical parameters inside the NMR 
spectra, through the verification of a strict relationship between their real values and 
the predicted ones through NMR analysis, as it has been done for cholesterol, 
triglicerides, LDL, HDL and ratio cholesterol-HDL, ii)to consider  also other parameters, 
such as smoke, alcohol and drugs intake and check their influence in the metabonomic 
profiles of the previously chosen classes, iii) to obtain one value, that can be 
considered as a score, that is sensitive of the metabolomic risk of cardiovascular 
disease and that is useful as evaluation parameter of the same risk, iv) highlight the 
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difference and the similarity between the “newborn” metabolomic risk and the 
classical risk, although actually it does not exist a clear and unique parameter of risk 
accepted by the international community (1), in order to understand difference, 
similarity, strength and weak points of the new approach, v) validate the results. 
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Besides the perspectives opened by each project, that are reported in proper section 
of each proper chapter, it is generally demonstrated the feasibility of metabolomics in 
the study and interpretation of various pathology. Therefore the metabolomics 
approach can be easily extended to some other pathologies. Indeed some other 
metabolomics projects are already started or are in a starting-phase. These new 
projects involve some widespread pathologies such as diabetes (type II), lung 
carcinoma, Obstructive and Chronic BroncoPathy (BPCO), liver cyrrhosis and 
carcinoma. The study of these new pathologies lead us to define better their 
characteristic, but also allow us to clearly understand what are the ideal targets and 
the limits of the metabolomic approach. Moreover, regarding the definition of 
metabotypes, it is necessary to univocally define what are the metabotypes and how 
exactly different metabotypes are related to different metabolic capacities of 
individuals. 
Furthermore it is necessary to continuously improve the step of the standardization of 
the samples. In general the metabolome changes depending on the body fluid tested, 
on the method of analysis, and on sample collection and handling. This highlights the 
need for the optimisation of pre-analytical tools for metabolomic analysis of biological 
samples, both because this is a relatively new technique and because the analytical 
technique itself is still undergoing optimisation. In other words, the technique itself 
cannot be advanced without the standardisation of sample selection and preparation. 
This is particularly true and necessary when it is analyzed some peculiar fluids, such as 
exhaled breath condensate or saliva for instance. Nevertheless, much research work is 
still needed in order to define the best protocols for sample collection and 
preparation. Sample handling and storage may strongly affect metabolomic profiles 
due to differing stabilities of the various metabolites. Even in the presence of 
“stability-optimised” samples, a strong limiting factor in the practical evaluation of 
diseases using a metabolomic approach lies in the intrinsic variability of human 
metabolic samples. Any study aimed at the identification of relevant metabolites 
should be presented with reference to the normal or control population. In order to be 
able to identify relevant metabolic changes, identification of metabolic fingerprint is 
usually needed as opposed to changes in concentration of a single biomarker. 
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However, the variations in metabolic fingerprinting are usually extremely small and 
therefore multiple sampling is required to eliminate the background noise due to 
personal variability. Sample collection, handling and storage are all critical steps for the 
detectability of metabolites by NMR and need to be optimised separately for each 
biofluid and tissue extract. For example NMR spectra of urine are dominated by 
thousands of sharp lines from predominantly low molecular mass metabolites, and the 
detectability of each metabolite is limited only by its concentration and stability over 
time. On the contrary, blood plasma and serum contain both low molecular and high 
molecular mass components. Tendency toward aggregation of proteins and protein-
small molecule interactions may cause disappearance of the signals of metabolites due 
to line broadening, even if the metabolites remain stable over time.  
Moreover this is valid also for statistical and NMR methods. The development of new 
simple 1D sequences of acquisition, an example is constituted by the 1D diffusion 
filtered acquisition (a sort of dosy1d), can be very useful to single out some 
information presented in samples, in case of 1D diffusion it is possible to obtain 
information about only macromolecules presented in serum, and in general in a 
biofluid. Moreover the development of new statistical analysis could further increase 
the quantity of obtainable data. 
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Sample Preparation 
All samples are collected in hospital structures and, immediately, frozen to – 80°C in 
order to avoid metabolites degradation. On the day of the analysis samples are thawed 
at room temperature and shaken before us. The following steps are slightly different 
basing on type of biofluids. Six hundred and thirty microliters of urine are added to 70 
microliters of a sodium phosphate buffer in deuterium oxide (2H2O). The buffer is 
principally constitued by  Na2HPO4 (0.2 M) and  NaH2PO4 (0.2 M); pH is standardized at 
7.0 to minimize variations in metabolite NMR chemical shifts. Moreover, the buffer 
also contains sodium trimethylsilyl [2,2,3,3-2H4]propionate (TSP) (10mM) and sodium 
azide (NaN3) (30mM), the first one is used to center the spectra at 0.00 ppm, the 
second one is a bacteriostatic.  Samples are centrifuged at 14 000g for 5 minutes to 
remove any solid debris. Blood samples, both serum and plasma, are simply prepared 
adding 300 microliters of them to  300 microliters of another sodium phosphate buffer 
in 20% (v/v) of 2H2O. The buffer contains  Na2HPO4 (70mM) and the pH is standardized 
at 7.4. Moreover, sodium trimethylsilyl [2,2,3,3-2H4]propionate (TSP) (0.8% w/v) and 
sodium azide (NaN3) (30mM) are present in the buffer. A total of 450 microliters of 
urine supernatant or serum are transferred into  4.25 mm outer-diameter NMR tubes. 
NMR Experiments and Bucketing 
One dimensional (1D) 1H NMR spectrum has been acquired at 600 MHz spectrometer. 
A spectrum of each sample is acquired with water peak suppression using a standard 
noesypresat1D pulse sequence. This sequence has been chosen in order to optimize 
sample acquisition basing on some parameters such as sensitivity, reproducibility and 
robustness. In particular it is chosen a presaturation sequence to partially erase the 
water peak because it is less invasive than other techniques as water gate-based 
(peaks are much easier  to integrate). Furthermore, the noesypresat1d sequence 
presents some advantages also with respect to standard zgpr and excitation sculpting 
(es). Indeed it is more sensitive than the sculpting for the absence of the shape pulses, 
and with respect to zgpr it is possible to experimentally have a better baseline. 
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Furthermore, serum samples are also acquired using a Carr-Purcell-Meiboom-Gill 
(CPMG) spin-echo sequence to suppress signals arising from high molecular weight 
molecules. This suppression is due to the capability of the mathematical CPMG filter to 
eliminate the signals with a short T2 such as macromolecules. Spectra are collected 
with 64 scans and 4 dummy scans. Thus the duration of each sequence is very short, 
about 8 minutes. Each 1D spectrum is segmented (in the range between 10.00 ppm 
and 0.02 ppm in to 0.02-ppm chemical shift buckets, and the corresponding spectral 
areas are integrated using AMIX software. Regions between 6.0 and 4.5 ppm, 
containing residual water and urea signals (in urine) are removed. The normalization is  
then carried out on the data prior to pattern recognition 
 
Multivariate Statistical Analysis 
Multivariate statistical analysis is a tool to examine relationships among a great 
number of statistical variables at the same time (multivariate data). Generally 
multivariate data are represented by a matrix. Each row of this matrix corresponds to 
an object, while each column is a peculiar and observable characteristic of the objects, 
for instance a bucket or a bin in metabolomics.  Many methods can be applied in order 
to perform a multivariate statistical analysis. Substantially the aim of these methods is 
obtaining a clusterization without giving data information to the systems 
(unsupervised methods). Basically, they search for correlating variables that allow a 
division of the objects into two or more classes. The principal and most used of these 
methods is PCA (Principal Components Analysis), even if other methods as HCA 
(Hierarchical Cluster Analysis) and Kohonen maps (also called SOMs) are used. 
Additionally to the X matrix containing data, another property, called y, may be given 
for each subject. This property adds a piece of information about the “nature” of each 
sample, as the class. These methods are supervised and therefore on a priori 
knowledge about subjects. The most common methods used are  PLS (Partial Least 
Square) regression (1) and their variants as O-PLS or K-PLS, but some other methods 
are also applied, as ANN (Artifical Neural Networks) and an informed version of 
Kohonen maps.  Moreover, both supervised and un-supervised methods are 
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frequently applied in combination with methods as Canonical Analysis (CA) and 
Regularized Canonical Analysis (RCC). These methods are usually applied on the 
PCA/PLS scores to enlarge the separation between the groups. After the separation 
step, it is necessary to classify the samples in order to decide which class each of them 
belongs to.. The principal tools to be applied in classification are k-Nearest Neighbor 
(k-NN) method, Linear Discriminant Analysis (LDA) (2) and derived methods, Support 
Vector Machine (SVM) method (3) and Random Forest method (4). 
The following step is the validation of the results.  The key of the validation of the NMR 
classification on class identity relies on Test Set Validation (TSV) approach which 
requires that models do not have any knowledge of the existence of any test set data. 
Monte Carlo cross-validation (MC), Leave One Out (LOO) validation and k-Fold 
validation are the principal  methods used in this step (5-6).  MC methods randomly 
split the dataset into two different set of data: training set and validation set. The 
training set is used to determine the statistical model, while the validation set is used 
to assess predictive accuracy. In k-Fold validation, the original dataset is divided into K 
subsets. K-1 subsets are used as training sets and the remaining subsets as validation 
sets.  Finally LOO works taking only one sample as validation set, whilst all other 
samples constitute the training set. All these methods are usually applied with 1000 
iterations, randomly varying the composition of both training and validation set, in 
order to obtain robust results. 
Finally, to assess which bucket is significantly different among various classes a one-
way analysis of variance is used. Normality of the data distributions is assessed using 
the Jarque-Bera normality test (7). Statistical significance of the means over the two 
groups is assessed using ANOVA or the non-parametric analogue Kruskal-Wallis test by 
using the Bonferroni correction on a nominal value of 0.005.  
Principal Component Analysis (PCA) 
PCA is an orthogonal linear combination of the original variables (normally called 
buckets or bins in metabolomics) in order to highlight the maximum variance among 
themselves. The mathematical formula can be expressed in this way: 
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                                                                             Y
T = W X T                
where X is the original matrix data and W is the matrix of the eigenvectors (see below) 
for linear combination. 
PCA was invented in 1901 by Karl Pearson, implemented in 1933 by Hotelling. The 
principal goal of PCA is the reduction of data, whilst it is retaining as much as possible 
the original variation present in the data set. This reduction is easily achieved by taking 
p variables from the data set (in metabolomics p buckets) X1, X2,…, Xp and linearly 
combining them to produce uncorrelated principal components (PCs) PC1, PC2,…, PCp. 
Moreover, these combinations are due so that the maximum variation among samples 
is expressed in PC1, the second greatest amount of variation in  PC2 and so on.  Clearly 
if the linear combination works well, the complete variability in the data set has to be 
adequately expressed by means of a few  PCs. Se vuoi dire pochi few, alcuni a few 
Mathematically the analysis is performed on a data set of p variables (X1, X2, … , Xp) 
for n individuals, as indicated below in Table 6.1. 
 
Table 6.1  Data matrix for principal component analysis 
It is necessary to calculate the corresponding covariance matrix:  
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where S is the covariance matrix,  sjk is the covariance of variables  Xj and Xk when j ≠ 
k and  the diagonal elements sjj represents the variance of variable Xj when j = k.   
original variation present in the data set. PCs and their associated eigenvalues are 
found in the sample covariance matrix through an iterative calculation process. 
In details, the first principal component (PC1) is then a linear combination of the 
original variables X1, X2, … , Xp, 
that varies as much as possible for the individuals, subject to the condition that 
 
where a11, a12… , a1pare coefficients assigned to the original p variables for PC1. 
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Therefore, the eigenvalue of PC1 is as large as possible given this constraint on the 
constant a1j. The constraint must be imposed in order to avoid the increasing of the 
eigenvalue of PC1 by simply increasing one or more of the a1j values. 
Similarly, the second principal component, 
 
is such that eigenvalues of PC2, are as large as possible subject to the constraint that: 
and also on the condition that PC2 is uncorrelated with PC1. The third principal 
component: 
 
is such that the eigenvalue of PC3 is as large as possible subject to the constraint that: 
 
and also on the condition that PC3, PC2 and PC1 are uncorrelated. All other principal 
components are obtained in a similar way. When  the eigenvectors (or PCs) are 
obtained, the following step is to select the components that better describe the 
system. Generally in PCA the number of extracted components is equal to the number 
of analyzed variables, but in general the last few components do not account for much 
of the variance and  can be ignored. It is not easy to identify the correct number of 
components that must be chosen to correctly describe a system. Someone suggests 
that the first 6 components explain 70% to 80% of the total variation. Probably  the 
best method to assess the adequate number of PCs is the so-called eigenvalue-one 
criterion (Kaiser criterion). Basing on this criterion, only the PCs that have eigenvalues 
higher or equal to one are retained. Indeed if a PC has an eigenvalue lower than 1, this 
means that contains less information than one of the original variables and it is 
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discarded. Actually the value of 1 as cut-off is considered too  selective and the correct 
cut-off value is experimentally determined in 0.7. However, the results of PCA are 
currently expressed in terms of scores (PCs) and loadings (eigenvalues).  
Partial Least Square (PLS) regression and derived methods 
The PLS is a common supervised method that was first introduced by Wold in 2001. It 
commonly relates to two different matrices: X, that usually contains spectral or 
chromatographic data, and Y, comprising quantitative characteristics of samples, as for 
instance class belongings. Substantially PLS finds the multidimensional direction in the 
X space that explains the maximum multidimensional variance direction in the Y space. 
PLS modelling is mathematically expressed by the following formulas:  
 
                                                                    X = TP
T 
+ E 
                                                                    Y = TC
T 
+ F 
 
where T is a score, or component, matrix (as see above for PCA), P and Q are 
respectively the loading matrices of X and Y and the terms E and F are the errors.  A 
recent development of PLS potentiality is obtained with OPLS. There is in OPLS the 
separation of X contribution in two parts: one is linearly related to Y matrix and the 
other one is orthogonal and, therefore, independent.          
                                                                    X = TpPp
T 
+
 
ToPo
T 
+ E 
                                                                    Y = TpCp 
T 
+ F            
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